Copyright © 2012 Helmut Bonkhoff. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. C. J. Rosser, M. Gaar, and S. Porvasnik, “Molecular fingerprinting of radiation resistant tumors: can we apprehend and rehabilitate the suspects?” BMC Cancer, vol. 9, p. 225, 2009. View at Scopus
2. M. Bolla, D. Gonzalez, P. Warde et al., “Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin,” The New England Journal of Medicine, vol. 337, no. 5, pp. 295–300, 1997. View at Publisher · View at Google Scholar · View at Scopus
3. M. Bolla, G. Van Tienhoven, P. Warde et al., “External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study,” The Lancet Oncology, vol. 11, no. 11, pp. 1066–1073, 2010. View at Publisher · View at Google Scholar · View at Scopus
4. M. Roach, F. Waldman, and A. Pollack, “Predictive models in external beam radiotherapy for clinically localized prostate cancer,” Cancer, vol. 115, supplement 13, pp. 3112–3120, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
5. C. Beard, D. Schultz, M. Loffredo et al., “Perineural invasion associated with increased cancer-specific mortality after external beam radiation therapy for men with low- and intermediate-risk prostate cancer,” International Journal of Radiation Oncology Biology Physics, vol. 66, no. 2, pp. 403–407, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
6. H. H. Yu, D. Y. Song, Y. Y. Tsai, T. Thompson, D. A. Frassica, and T. L. DeWeese, “Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy,” Urology, vol. 70, no. 1, pp. 111–116, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
7. A. A. Roma, C. Magi-Galluzzi, M. A. Kral, T. T. Jin, E. A. Klein, and M. Zhou, “Peritumoral lymphatic invasion is associated with regional lymph node metastases in prostate adenocarcinoma,” Modern Pathology, vol. 19, no. 3, pp. 392–398, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
8. M. K. Ferrari, J. E. McNeal, S. M. Malhotra, and J. D. Brooks, “Vascular invasion predicts recurrence after radical prostatectomy: stratification of risk based on pathologic variables,” Urology, vol. 64, no. 4, pp. 749–753, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
9. L. Cheng, T. D. Jones, H. Lin et al., “Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma,” Journal of Urology, vol. 174, no. 6, pp. 2181–2185, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
10. S. F. Shariat, S. M. Khoddami, H. Saboorian et al., “Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy,” Journal of Urology, vol. 171, no. 3, pp. 1122–1127, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
11. J. P. Brooks, P. S. Albert, J. O'Connell, D. G. McLeod, and M. M. Poggi, “Lymphovascular invasion in prostate cancer: prognostic significance in patients treated with radiotherapy after radical prostatectomy,” Cancer, vol. 106, no. 7, pp. 1521–1526, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
12. V. Pagliarulo, D. Hawes, F. H. Brands et al., “Detection of occult lymph node metastases in locally advanced node-negative prostate cancer,” Journal of Clinical Oncology, vol. 24, no. 18, pp. 2735–2742, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
13. B. J. Feldman and D. Feldman, “The development of androgen-independent prostate cancer,” Nature Reviews Cancer, vol. 1, no. 1, pp. 34–45, 2001. View at Scopus
14. K. J. Pienta and D. Bradley, “Mechanisms underlying the development of androgen-independent prostate cancer,” Clinical Cancer Research, vol. 12, no. 6, pp. 1665–1671, 2006. View at Publisher · View at Google Scholar · View at PubMed
15. R. S. Taichman, R. D. Loberg, R. Mehra, and K. J. Pienta, “The evolving biology and treatment of prostate cancer,” Journal of Clinical Investigation, vol. 117, no. 9, pp. 2351–2361, 2007. View at Publisher · View at Google Scholar · View at PubMed
16. H. Bonkhoff and R. Berges, “From pathogenesis to prevention of castration resistant prostate cancer,” The Prostate, vol. 70, no. 1, pp. 100–112, 2010. View at Publisher · View at Google Scholar · View at PubMed
17. C. A. Heinlein and C. Chang, “Androgen receptor in prostate cancer,” Endocrine Reviews, vol. 25, no. 2, pp. 276–308, 2004. View at Publisher · View at Google Scholar
18. Z. Culig, “Androgen receptor cross-talk with cell signalling pathways,” Growth Factors, vol. 22, no. 3, pp. 179–184, 2004. View at Publisher · View at Google Scholar
19. C. D. Chen, D. S. Welsbie, C. Tran et al., “Molecular determinants of resistance to antiandrogen therapy,” Nature Medicine, vol. 10, no. 1, pp. 33–39, 2004. View at Publisher · View at Google Scholar · View at PubMed
20. M. L. Zhu and N. Kyprianou, “Androgen receptor and growth factor signaling cross-talk in prostate cancer cells,” Endocrine-Related Cancer, vol. 15, no. 4, pp. 841–849, 2008. View at Publisher · View at Google Scholar · View at PubMed
21. R. P. Singh and R. Agarwal, “Mechanisms of action of novel agents for prostate cancer chemoprevention,” Endocrine-Related Cancer, vol. 13, no. 3, pp. 751–778, 2006. View at Publisher · View at Google Scholar · View at PubMed
22. P. Singh, A. Uzgare, I. Litvinov, S. R. Denmeade, and J. T. Isaacs, “Combinatorial androgen receptor targeted therapy for prostate cancer,” Endocrine-Related Cancer, vol. 13, no. 3, pp. 653–666, 2006. View at Publisher · View at Google Scholar · View at PubMed
23. K. N. Chi, A. Bjartell, D. Dearnaley et al., “Castration-resistant prostate cancer: from new pathophysiology to new treatment targets,” European Urology, vol. 56, no. 4, pp. 594–605, 2009. View at Publisher · View at Google Scholar · View at PubMed
24. R. Li, T. Wheeler, H. Dai, A. Frolov, T. Thompson, and G. Ayala, “High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy,” The American Journal of Surgical Pathology, vol. 28, no. 7, pp. 928–934, 2004. View at Publisher · View at Google Scholar · View at Scopus
25. S. M. Henshall, D. I. Quinn, C. S. Lee et al., “Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer,” Cancer Research, vol. 61, no. 2, pp. 423–427, 2001. View at Scopus
26. M. J. Donovan, S. Hamann, M. Clayton et al., “Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy,” Journal of Clinical Oncology, vol. 26, no. 24, pp. 3923–3929, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
27. I. L. Rosner, L. Ravindranath, B. Furusato et al., “Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy,” Urology, vol. 70, no. 6, pp. 1225–1229, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
28. M. J. Donovan, F. M. Khan, G. Fernandez et al., “Personalized prediction of tumor response and cancer progression on prostate needle biopsy,” Journal of Urology, vol. 182, no. 1, pp. 125–132, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
29. D. I. Quinn, S. M. Henshall, and R. L. Sutherland, “Molecular markers of prostate cancer outcome,” European Journal of Cancer, vol. 41, no. 6, pp. 858–887, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
30. L. Cheng, R. V. Lloyd, A. L. Weaver et al., “The cell cycle inhibitors p21(WAF1) and p27(KIP1) are associated with survival in patients treated by salvage prostatectomy after radiation therapy,” Clinical Cancer Research, vol. 6, no. 5, pp. 1896–1899, 2000. View at Scopus
31. H. H. Hensley, J. M. Hannoun-Levi, P. Hachem et al., “PKA knockdown enhances cell killing in response to radiation and androgen deprivation,” International Journal of Cancer, vol. 128, no. 4, pp. 962–973, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
32. A. Pollack, K. Bae, L. Y. Khor et al., “The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02,” Clinical Cancer Research, vol. 15, no. 17, pp. 5478–5484, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
33. J. Karar and A. Maity, “Modulating the tumor microenvironment to increase radiation responsiveness,” Cancer Biology and Therapy, vol. 8, no. 21, pp. 1994–2001, 2009. View at Scopus
34. B. B. Aggarwal, R. V. Vijayalekshmi, and B. Sung, “Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe,” Clinical Cancer Research, vol. 15, no. 2, pp. 425–430, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
35. J. S. Ross, B. V. Kallakury, C. E. Sheehan et al., “Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence,” Clinical Cancer Research, vol. 10, no. 7, pp. 2466–2472, 2004. View at Publisher · View at Google Scholar · View at Scopus
36. R. J. Jin, Y. Lho, L. Connelly et al., “The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth,” Cancer Research, vol. 68, no. 16, pp. 6762–6769, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
37. J. Abdulghani, L. Gu, A. Dagvadorj et al., “Stat3 promotes metastatic progression of prostate cancer,” The American Journal of Pathology, vol. 172, no. 6, pp. 1717–1728, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
38. C. J. Rosser, A. O. Reyes, F. Vakar-Lopez et al., “Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma,” International Journal of Radiation Oncology Biology Physics, vol. 56, no. 1, pp. 1–6, 2003. View at Publisher · View at Google Scholar · View at Scopus
39. P. A. Di Sant'Agnese, “Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments,” Annals of Oncology, vol. 12, supplement 2, pp. S135–S140, 2001. View at Scopus
40. H. Bonkhoff, “Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status,” The Prostate, vol. 36, supplement 8, pp. 18–22, 1998. View at Scopus
41. H. Bonkhoff, “Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status,” Annals of Oncology, vol. 12, supplement 2, pp. S141–S144, 2001. View at Scopus
42. T. Fixemer, K. Remberger, and H. Bonkhoff, “Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma,” The Prostate, vol. 53, no. 2, pp. 118–123, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
43. G. S. Palapattu, C. Wu, C. R. Silvers et al., “Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer,” The Prostate, vol. 69, no. 7, pp. 787–798, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
44. W. Lilleby, E. Paus, E. Skovlund, and S. D. Fosså, “Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer,” The Prostate, vol. 46, no. 2, pp. 126–133, 2001. View at Publisher · View at Google Scholar · View at Scopus
45. T. Hvamstad, A. Jordal, N. Hekmat, E. Paus, and S. D. Fosså, “Neuroendocrine serum tumour markers in hormone-resistant prostate cancer,” European Urology, vol. 44, no. 2, pp. 215–221, 2003. View at Publisher · View at Google Scholar · View at Scopus
46. B. A. Narayanan, B. S. Reddy, M. C. Bosland et al., “Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence,” Clinical Cancer Research, vol. 13, no. 19, pp. 5965–5973, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
47. L. Y. Khor, K. Bae, A. Pollack et al., “COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial,” The Lancet Oncology, vol. 8, no. 10, pp. 912–920, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
48. L. Y. Khor, K. Bae, R. Paulus et al., “MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02,” Journal of Clinical Oncology, vol. 27, no. 19, pp. 3177–3184, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
49. R. Stoyanova, P. Hachem, H. Hensley et al., “Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo,” International Journal of Radiation Oncology Biology Physics, vol. 68, no. 4, pp. 1151–1160, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
50. H. Bonkhoff and K. Remberger, “Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model,” The Prostate, vol. 28, no. 2, pp. 98–106, 1996. View at Publisher · View at Google Scholar · View at Scopus
51. W. Liu, S. Laitinen, S. Khan et al., “Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer,” Nature Medicine, vol. 15, no. 5, pp. 559–565, 2009. View at Publisher · View at Google Scholar · View at PubMed
52. A. T. Collins, P. A. Berry, C. Hyde, M. J. Stower, and N. J. Maitland, “Prospective identification of tumorigenic prostate cancer stem cells,” Cancer Research, vol. 65, no. 23, pp. 10946–10951, 2005. View at Publisher · View at Google Scholar · View at PubMed
53. H. I. Scher, T. M. Beer, C. S. Higano, et al., “Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study,” The Lancet, vol. 375, no. 9724, pp. 1437–1446, 2010.
54. M. A. Kollmeier, M. S. Katz, K. Mak et al., “Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 79, no. 3, pp. 713–718, 2011. View at Publisher · View at Google Scholar · View at PubMed
55. R. Gutt, N. Tonlaar, R. Kunnavakkam, T. Karrison, R. R. Weichselbaum, and S. L. Liauw, “Statin use and risk of prostate cancer recurrence in men treated with radiation therapy,” Journal of Clinical Oncology, vol. 28, no. 16, pp. 2653–2659, 2010. View at Publisher · View at Google Scholar · View at PubMed
56. R. B. Montgomery, E. A. Mostaghel, R. Vessella et al., “Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth,” Cancer Research, vol. 68, no. 11, pp. 4447–4454, 2008. View at Publisher · View at Google Scholar · View at PubMed
57. G. Joensuu, T. Joensuu, P. Nokisalmi et al., “A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer,” International Journal of Radiation Oncology Biology Physics, vol. 78, no. 1, pp. 42–49, 2010. View at Publisher · View at Google Scholar · View at PubMed
58. C. Nabhan, T. M. Lestingi, A. Galvez et al., “Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial,” Urology, vol. 74, no. 3, pp. 665–671, 2009. View at Publisher · View at Google Scholar · View at PubMed
59. D. Sarker, A. H. Reid, T. A. Yap, and J. S. de Bono, “Targeting the PI3K/AKT pathway for the treatment of prostate cancer,” Clinical Cancer Research, vol. 15, no. 15, pp. 4799–4805, 2009. View at Publisher · View at Google Scholar · View at PubMed
60. K. Camphausen and P. J. Tofilon, “Inhibition of Hsp90: a multitarget approach to radiosensitization,” Clinical Cancer Research, vol. 13, no. 15, pp. 4326–4330, 2007. View at Publisher · View at Google Scholar · View at PubMed
61. T. Yoshino, H. Shiina, S. Urakami et al., “Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy,” Clinical Cancer Research, vol. 12, no. 20, pp. 6116–6124, 2006. View at Publisher · View at Google Scholar · View at PubMed
62. F. Di Silverio, A. Sciarra, and V. Gentile, “Etoricoxib and intermittent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy,” Urology, vol. 71, no. 5, pp. 947–951, 2008. View at Publisher · View at Google Scholar · View at PubMed
63. R. S. Pruthi, J. E. Derksen, D. Moore et al., “Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy,” Clinical Cancer Research, vol. 12, no. 7 I, pp. 2172–2177, 2006. View at Publisher · View at Google Scholar · View at PubMed
64. R. S. Pruthi, J. E. Derksen, and D. Moore, “A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy,” The British Journal of Urology International, vol. 93, no. 3, pp. 275–278, 2004. View at Publisher · View at Google Scholar
65. A. Sciarra, C. Bosman, G. Monti, et al., “Combiation therapy of ethinylestadiol and soamtostatin analogue reintroduces objective clinical responses and decreases chromogranin A in patients with androgen ablation refractory prostate cancer,” Journal of Urology, vol. 170, pp. 1812–1816, 2003.
66. M. Koutsilieris, C. Mitsiades, T. Dimopoulos, A. Ioannidis, A. Ntounis, and T. Lambou, “A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 12, pp. 5729–5736, 2001. View at Publisher · View at Google Scholar
67. C. S. Mitsiades, J. Bogdanos, D. Karamanolakis, C. Milathianakis, T. Dimopoulos, and M. Koutsilieris, “Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer,” Anticancer Research, vol. 26, no. 5, pp. 3693–3700, 2006.
68. A. Dubrovska, J. Elliott, R. J. Salamone et al., “Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma,” Clinical Cancer Research, vol. 16, no. 23, pp. 5692–5702, 2010. View at Publisher · View at Google Scholar · View at PubMed
69. S. U. Luk, W. N. Yap, Y. T. Chiu, et al., “Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population,” International Journal of Cancer, vol. 128, no. 9, pp. 2182–2191, 2011.
70. J. A. Bonner, P. M. Harari, J. Giralt et al., “Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck,” The New England Journal of Medicine, vol. 354, no. 6, pp. 567–578, 2006. View at Publisher · View at Google Scholar · View at PubMed
71. H. Ammar and J. L. Closset, “Clusterin activates survival through the phosphatidylinositol 3-kinase/Akt pathway,” Journal of Biological Chemistry, vol. 283, no. 19, pp. 12851–12861, 2008. View at Publisher · View at Google Scholar · View at PubMed
72. L. V. July, M. Akbari, T. Zellweger, E. C. Jones, S. L. Goldenberg, and M. E. Gleave, “Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy,” The Prostate, vol. 50, no. 3, pp. 179–188, 2002. View at Publisher · View at Google Scholar · View at PubMed
73. T. Zellweger, K. Chi, H. Miyake et al., “Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin,” Clinical Cancer Research, vol. 8, no. 10, pp. 3276–3284, 2002.
74. A. Sciarra, G. Mariotti, V. Gentile et al., “Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable?” The British Journal of Urology International, vol. 91, no. 5, pp. 438–445, 2003. View at Publisher · View at Google Scholar
75. A. Sciarra, S. Monti, V. Gentile, et al., “Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma,” Urology, vol. 63, pp. 523–537, 2004.
76. A. Sciarra, S. Monti, V. Gentile et al., “Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma,” The Prostate, vol. 55, no. 3, pp. 168–179, 2003. View at Publisher · View at Google Scholar · View at PubMed
77. A. Komiya, H. Suzuki, T. Imamoto et al., “Neuroendocrine differentiation in the progression of prostate cancer,” International Journal of Urology, vol. 16, no. 1, pp. 37–44, 2009. View at Publisher · View at Google Scholar · View at PubMed